Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1). 

Biotechnology

Alcyone Therapeutics

Alcyone Therapeutics' headquarters in Lowell, MA, United States

Pj Anand

Bryn Martin

Rich Upton

John L. McGuire

David Johnson

Burt Raymond

Andrew East

Ravi Mehrotra

Nicolas Wein

Maurizio Pellechia

Sanchita Bhatnagar

Isabelle Aubert

Laura Ferraiuolo

Dave Arnold

Timothy Benke

Edgar D. Jannotta, Jr.

Dennis Durbin

Cameron Durrant

Richard Upton

Piratip Pratumsuwan

Stephen Oesterle

David Donabedian

Jeffrey L. Neul

Roxana O Carare

Kathrin Meyer

Description

People (10)

Burt Raymond

David Johnson

John L. McGuire

Rich Upton

Caraline Wood

Natalia Podporina

Todd Washburn

Andrea Steenstrup

Bonnie Szarzynski McIsaac

Rachael Coughlin (Kozera)

Jobs